This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Co-morbidities in SLE (systemic lupus erythematosus)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Co-morbidities in SLE

Patients with SLE are at an increase risk of several co-morbidities when compared with the general population (1,2):

  • can be either disease related morbidity or treatment related morbidity
  • the following co-morbidities have been identified in lupus patients
    • cardiovascular diseases
      • e.g. - hypertension, dyslipidaemia
      • the risk is 5-6 times higher when compared to healthy controls
      • additionally lupus patients have a predisposition to premature atherosclerosis due to lupus-specific factors such as disease activity, renal disease and corticosteroid use.
    • osteoporosis
      • risk factors for reduced bone mineral density (BMD) include age, low body weight, inflammatory markers (ESR and CRP) and pre-existing organ damage
      • corticosteroid doses of >7.5 mg in particular are associated with a greater risk of osteoporosis
    • infection
      • remains the primary cause of mortality in approximately 25% patients with SLE
      • bacterial infections (specially pneumonia) are the most common reason for hospitalisation due to infection
      • most common
        • viral pathogen - herpes zoster
        • bacterial pathogen - S. pneumoniae, E. coli and S. aureus
      • both disease-related factors (lung involvement, renal disease, lymphopenia, complement consumption and functional hyposplenism) and drug-related effects (cumulative steroid exposure and immunosuppressant use) may increase the risk of infection
    • certain types of cancer (non-Hodgkin's lymphoma, lung cancer, hepatobiliary cancer)
    • thromboembolic disease

References:

  1. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report Ann Rheum Dis. 2008 Feb;67(2)
  2. M Zen et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study. European Journal of Internal Medicine. Volume 112. p45-51 June 2023

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.